William R. Schief

Active 1996–2026

135
Papers
22,818
Citations
79
h-index
126
i10-index

Citations

Citations per year for William R. Schief1981: 1 citations1988: 1 citations1995: 1 citations1997: 3 citations1998: 5 citations2000: 2 citations2001: 10 citations2002: 7 citations2003: 11 citations2004: 21 citations2005: 40 citations2006: 16 citations2007: 16 citations2008: 26 citations2009: 19 citations2010: 44 citations2011: 110 citations2012: 168 citations2013: 275 citations2014: 212 citations2015: 273 citations2016: 365 citations2017: 363 citations2018: 407 citations2019: 955 citations2020: 1,098 citations2021: 1,111 citations2022: 886 citations2023: 822 citations2024: 1,333 citations2025: 842 citations2026: 47 citations1982–1987: no citations, so these years are not shown1989–1994: no citations, so these years are not shown1996: no citations, so this year is not shown1999: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,662 citing papers, 38.2% of this breakdownChina: 607 citing papers, 8.7% of this breakdownUnited Kingdom: 468 citing papers, 6.7% of this breakdownGermany: 345 citing papers, 4.9% of this breakdownFrance: 231 citing papers, 3.3% of this breakdownNetherlands: 231 citing papers, 3.3% of this breakdownCanada: 228 citing papers, 3.3% of this breakdownSwitzerland: 211 citing papers, 3% of this breakdownAustralia: 152 citing papers, 2.2% of this breakdownItaly: 134 citing papers, 1.9% of this breakdownSouth Africa: 128 citing papers, 1.8% of this breakdownSweden: 117 citing papers, 1.7% of this breakdown
0%38.2%Other 21%

Fields

  • Immunology and Microbiology33.7%
  • Medicine29.3%
  • Biochemistry, Genetics and Molecular Biology28%
  • Pharmacology, Toxicology and Pharmaceutics2.1%
  • Computer Science1.1%
  • Materials Science1.1%
  • Other4.7%

Topics

  • HIV Research and Treatment8.8%
  • Monoclonal and Polyclonal Antibodies Research6.9%
  • Immunotherapy and Immune Responses5.3%
  • Immune Cell Function and Interaction4.8%
  • vaccines and immunoinformatics approaches4.5%
  • SARS-CoV-2 and COVID-19 Research4.3%
  • Other65.4%

Coauthors

All papers

Open in search
  1. Macromolecular modeling and design in Rosetta: recent methods and frameworks

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lukasz Goldschmidt, Ragul Gowthaman, Jeffrey J. Gray, Dominik Gront, Sharon L. Guffy, Scott Horowitz, Po‐Ssu Huang, Thomas Huber, Timothy M. Jacobs, Jeliazko R. Jeliazkov, David K. Johnson, Kalli Kappel, John Karanicolas, Hamed Khakzad, Karen R. Khar, Sagar D. Khare, Firas Khatib, Alisa Khramushin, Indigo C. King, Robert Kleffner, Brian Koepnick, Tanja Kortemme, Georg Kuenze, Brian Kuhlman, Daisuke Kuroda, Jason W. Labonte, Jason Lai, Gideon Lapidoth, Andrew Leaver‐Fay, Steffen Lindert, Thomas W. Linsky, Nir London, Joseph H. Lubin, Sergey Lyskov, Jack B. Maguire, Lars Malmström, Enrique Marcos, Orly Marcu, Nicholas Marze, Jens Meiler, Rocco Moretti, Vikram Khipple Mulligan, Santrupti Nerli, Christoffer Norn, Shane Ó’Conchúir, Noah Ollikainen, Sergey Ovchinnikov, Michael S. Pacella, Xingjie Pan, Hahnbeom Park, Ryan E. Pavlovicz, Manasi A. Pethe, Brian G. Pierce, Kala Bharath Pilla, Barak Raveh, P. Douglas Renfrew, Shourya S. Roy Burman, Aliza B. Rubenstein, Marion F. Sauer, Andreas Scheck, William R. Schief, Ora Schueler‐Furman, Yuval Sedan, Alexander M. Sevy, Nikolaos G. Sgourakis, Lei Shi, Justin B. Siegel, Daniel‐Adriano Silva, Shannon T. Smith, Yifan Song and 8 more - Nature Methods 2020 cited by 923

  2. Vaccination induces HIV broadly neutralizing antibody precursors in humans

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David M. Brown, David R. Ambrozak, Troy Sincomb, Xiaozhen Hu, Ryan Tingle, Erik Georgeson, Saman Eskandarzadeh, Nushin Alavi, Danny Lu, Tina-Marie Mullen, Michael Kubitz, Bettina Gröschel, Janine Maenza, Orpheus Kolokythas, Nadia J. Khati, Jeffrey M. Bethony, Shane Crotty, Mario Roederer, Gunilla B. Karlsson Hedestam, Georgia D. Tomaras, David C. Montefiori, David Diemert, Richard A. Koup, Dagna Laufer, M. Juliana McElrath, Adrian B. McDermott, William R. Schief - Science 2022 cited by 272

  3. Role of nanoscale antigen organization on B-cell activation probed using DNA origami

    Authors: , , , , , , , , , , - Nature Nanotechnology 2020 cited by 442

  4. Long-primed germinal centres with enduring affinity maturation and clonal migration

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David C. Montefiori, Ronald S. Veazey, Andrew B. Ward, Lars Hangartner, Dennis R. Burton, Darrell J. Irvine, William R. Schief, Shane Crotty - Nature 2022 cited by 192

  5. Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Corey T. Watson, Guido Silvestri, Darrell J. Irvine, Shane Crotty - Cell 2019 cited by 470

  6. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science 2010 cited by 1,802

  7. Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors

    Authors: , , , , , , , , , , , , , , , , , , - Science 2013 cited by 822

  8. Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo

    Authors: , , , , , , , , , - Immunity 2020 cited by 281

  9. RosettaAntibodyDesign (RAbD): A general framework for computational antibody design

    Authors: , , , , , , , - PLoS Computational Biology, PLoS Comput. Biol. 2008 cited by 230

  10. A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , William R. Schief - Science 2019 cited by 284

  11. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Diane G. Carnathan, Daniel Lingwood, Dennis R. Burton, Galit Alter, Timothy P. Padera, Angela M. Belcher, William R. Schief, Guido Silvestri, Ruth M. Ruprecht, Shane Crotty, Darrell J. Irvine - Science Immunology 2021 cited by 174

  12. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen

    Authors: , , , , , , , , , , , , , , , , , , , , , - Science 2016 cited by 483

  13. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2016 cited by 445

  14. Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2022 cited by 157

  15. Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens

    Authors: , , , , , , , , , , , , - Immunity 2017 cited by 367

  16. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers

    Authors: , , , , , , , , , , , , , , , - Science 2018 cited by 312

  17. Engineered immunogen binding to alum adjuvant enhances humoral immunity

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2020 cited by 267

  18. Proof of principle for epitope-focused vaccine design

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature, Nat. 2011 cited by 587

  19. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen

    Authors: , , , , , , , , , , , , , , , , , - Science 2015 cited by 439

  20. RosettaRemodel: A Generalized Framework for Flexible Backbone Protein Design

    Authors: , , , , , , - PLoS ONE 2011 cited by 414

  21. Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric Georgeson, Sergey Menis, Daniel C. Douek, William R. Schief, Leonidas Stamatatos, Peter D. Kwong, Lawrence Shapiro, Barton F. Haynes, John R. Mascola, Frederick W. Alt - Cell 2016 cited by 258

  22. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Devin Sok, Andrew B. Ward, William R. Schief, Facundo D. Batista - Science 2024 cited by 66

  23. Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Torben Schiffner, Dennis R. Burton, Corey T. Watson, Steven E. Bosinger, Max Crispin, John R. Yates, James C. Paulson, Andrew B. Ward, Devin Sok, Shane Crotty, William R. Schief - Science 2024 cited by 65

  24. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , M. Juliana McElrath - Science Translational Medicine 2023 cited by 70